Topics
Treatment, Outcomes / Survival
Modality
Immunotherapy, Targeted therapy, Imaging
Study type
Not listed
Abstract
Anti-PD-(L)1 agents, inhibitors of programmed cell death protein 1 (PD-1) or its ligand (PD-L1), are established therapies that improve cancer management as well as the disease and societal burden of specific metastatic and early-stage cancers. The aim of the study was to determine the…
Authors
Daniel Ladino, Karl Patterson, Máté Várnai, Éva Balogh +2
AI-generated summary
Health and productivity benefits of anti-PD-(L)1 agents for early-stage cancer treatment in Hungary. reports: Anti-PD-(L)1 agents, inhibitors of programmed cell death protein 1 (PD-1) or its ligand (PD-L1), are established therapies that improve cancer management as well as the disease and societal burden of specific metastatic and early-stage cancers. The aim of the study was to determine the impact of adopting anti-PD-(L)1 agents for the treatment of all eligible patients with early-stage cancers versus reserving anti-PD-(L)1 agents for patients with metastatic disease alone in Hungary. This study evaluated two scenarios, one where anti-PD-(L)1 agents were used to treat all eligible early-stage disease case s (ESD scenario) of melanoma (stage IIB-C and III), renal cell carcinoma (RCC), and triple-negative breast cancer (TNBC) versus a reference scenario where anti-PD-(L)1 agents were only used to treat metastatic disease cases in Hungary (2024-2033).
This summary may be inaccurate. Verify with the primary paper.
Primary source: PubMed.